281 related articles for article (PubMed ID: 15613191)
21. Psychopharmacologic treatment of adolescent depression.
Lynch A; Glod CA; Fitzgerald F
Arch Psychiatr Nurs; 2001 Feb; 15(1):41-7. PubMed ID: 11172238
[TBL] [Abstract][Full Text] [Related]
22. S-fluoxetine in the prophylaxis of migraine: a phase II double-blind randomized placebo-controlled study.
Steiner TJ; Ahmed F; Findley LJ; MacGregor EA; Wilkinson M
Cephalalgia; 1998 Jun; 18(5):283-6. PubMed ID: 9673809
[TBL] [Abstract][Full Text] [Related]
23. Venlafaxine extended release (XR) for the prophylaxis of migraine and tension-type headache: A retrospective study in a clinical setting.
Adelman LC; Adelman JU; Von Seggern R; Mannix LK
Headache; 2000; 40(7):572-80. PubMed ID: 10940096
[TBL] [Abstract][Full Text] [Related]
24. Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial.
Kroenke K; West SL; Swindle R; Gilsenan A; Eckert GJ; Dolor R; Stang P; Zhou XH; Hays R; Weinberger M
JAMA; 2001 Dec; 286(23):2947-55. PubMed ID: 11743835
[TBL] [Abstract][Full Text] [Related]
25. Canadian Headache Society guideline for migraine prophylaxis.
Pringsheim T; Davenport W; Mackie G; Worthington I; Aubé M; Christie SN; Gladstone J; Becker WJ;
Can J Neurol Sci; 2012 Mar; 39(2 Suppl 2):S1-59. PubMed ID: 22683887
[TBL] [Abstract][Full Text] [Related]
26. Treatment of functional dyspepsia with sertraline: a double-blind randomized placebo-controlled pilot study.
Tan VP; Cheung TK; Wong WM; Pang R; Wong BC
World J Gastroenterol; 2012 Nov; 18(42):6127-33. PubMed ID: 23155342
[TBL] [Abstract][Full Text] [Related]
27. Granisetron-mediated augmentation of sertraline therapeutic effect in obsessive-compulsive disorder: a double-blind placebo-controlled, randomized clinical trial.
Ghobadian A; Mokhtari S; Shariati B; Kamalzadeh L; Shati M; Eftekhar Ardebili M; Yarahmadi M; Shalbafan M
BMC Pharmacol Toxicol; 2022 Sep; 23(1):73. PubMed ID: 36167636
[TBL] [Abstract][Full Text] [Related]
28. Additional dopamine reuptake inhibition attenuates vigilance impairment induced by serotonin reuptake inhibition in man.
Schmitt JA; Ramaekers JG; Kruizinga MJ; van Boxtel MP; Vuurman EF; Riedel WJ
J Psychopharmacol; 2002 Sep; 16(3):207-14. PubMed ID: 12236626
[TBL] [Abstract][Full Text] [Related]
29. Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression.
Thase ME; Nierenberg AA; Vrijland P; van Oers HJ; Schutte AJ; Simmons JH
Int Clin Psychopharmacol; 2010 Jul; 25(4):189-98. PubMed ID: 20531012
[TBL] [Abstract][Full Text] [Related]
30. Tricyclic antidepressants and headaches: systematic review and meta-analysis.
Jackson JL; Shimeall W; Sessums L; Dezee KJ; Becher D; Diemer M; Berbano E; O'Malley PG
BMJ; 2010 Oct; 341():c5222. PubMed ID: 20961988
[TBL] [Abstract][Full Text] [Related]
31. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder.
Mataix-Cols D; Rauch SL; Manzo PA; Jenike MA; Baer L
Am J Psychiatry; 1999 Sep; 156(9):1409-16. PubMed ID: 10484953
[TBL] [Abstract][Full Text] [Related]
32. Relationship between plasma melatonin levels and the efficacy of selective serotonin reuptake inhibitors treatment on premature ejaculation.
Kirecci SL; Simsek A; Gurbuz ZG; Mimaroglu S; Yuksel A; Vural P; Degirmencioglu S
Int J Urol; 2014 Sep; 21(9):917-20. PubMed ID: 24712716
[TBL] [Abstract][Full Text] [Related]
33. Sertraline delays relapse in recently abstinent cocaine-dependent patients with depressive symptoms.
Oliveto A; Poling J; Mancino MJ; Williams DK; Thostenson J; Pruzinsky R; Gonsai K; Sofuoglu M; Gonzalez G; Tripathi S; Kosten TR
Addiction; 2012 Jan; 107(1):131-41. PubMed ID: 21707811
[TBL] [Abstract][Full Text] [Related]
34. A comparison of the effects of different serotonin reuptake blockers on sexual behaviour of the male rat.
Mos J; Mollet I; Tolboom JT; Waldinger MD; Olivier B
Eur Neuropsychopharmacol; 1999 Jan; 9(1-2):123-35. PubMed ID: 10082238
[TBL] [Abstract][Full Text] [Related]
35. Exacerbation of migraine attacks during treatment with the selective serotonin reuptake inhibitor sertraline. A case report.
Bickel A; Kornhuber J; Maihöfner C; Ropohl A
Pharmacopsychiatry; 2005 Nov; 38(6):327-8. PubMed ID: 16342007
[TBL] [Abstract][Full Text] [Related]
36. Combined treatment with sertraline and liothyronine in major depression: a randomized, double-blind, placebo-controlled trial.
Cooper-Kazaz R; Apter JT; Cohen R; Karagichev L; Muhammed-Moussa S; Grupper D; Drori T; Newman ME; Sackeim HA; Glaser B; Lerer B
Arch Gen Psychiatry; 2007 Jun; 64(6):679-88. PubMed ID: 17548749
[TBL] [Abstract][Full Text] [Related]
37. Sertraline: a review of its use in the management of major depressive disorder in elderly patients.
Muijsers RB; Plosker GL; Noble S
Drugs Aging; 2002; 19(5):377-92. PubMed ID: 12093324
[TBL] [Abstract][Full Text] [Related]
38. Sertraline treatment of panic disorder: response in patients at risk for poor outcome.
Pollack MH; Rapaport MH; Clary CM; Mardekian J; Wolkow R
J Clin Psychiatry; 2000 Dec; 61(12):922-7. PubMed ID: 11206597
[TBL] [Abstract][Full Text] [Related]
39. Sertraline versus paroxetine in major depression: clinical outcome after six months of continuous therapy.
Aberg-Wistedt A; Agren H; Ekselius L; Bengtsson F; Akerblad AC
J Clin Psychopharmacol; 2000 Dec; 20(6):645-52. PubMed ID: 11106136
[TBL] [Abstract][Full Text] [Related]
40. Sertraline and cognitive behavioral therapy for depressed alcoholics: results of a placebo-controlled trial.
Moak DH; Anton RF; Latham PK; Voronin KE; Waid RL; Durazo-Arvizu R
J Clin Psychopharmacol; 2003 Dec; 23(6):553-62. PubMed ID: 14624185
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
